What Is Progesterone

Progesterone is a steroid hormone produced mainly by the corpus luteum of the ovaries after ovulation, with smaller amounts synthesized by the adrenal glands and, during pregnancy, by the placenta. It prepares and maintains the uterine lining for implantation, and its levels rise and fall in a predictable pattern across the menstrual cycle. Beyond reproduction, progesterone acts on the brain, bones, cardiovascular system, and immune function, making it relevant to long-term health well past the childbearing years.

Progesterone's influence extends far beyond fertility. It is a neurosteroid, meaning it crosses the blood-brain barrier and directly modulates brain signaling, particularly through GABA-A receptors. This action underlies its effects on sleep quality, anxiety, and emotional stability. When progesterone declines during perimenopause and menopause, many women experience disrupted sleep, heightened anxiety, and changes in mood that are often attributed to aging rather than to a specific hormonal deficit.

From a longevity perspective, progesterone contributes to bone mineral density by stimulating osteoblast activity, complementing estrogen's role in slowing bone resorption. It also counterbalances estrogen's growth-promoting effects on breast and uterine tissue, which is why progesterone (or a progestin) is prescribed alongside estrogen in hormone replacement therapy for women with an intact uterus. Its role in cardiovascular health, immune modulation, and myelin repair adds further relevance. Understanding progesterone as more than a "pregnancy hormone" reframes how women and their clinicians approach symptoms throughout the second half of life.

Progesterone biosynthesis begins with cholesterol. Through a series of enzymatic steps, cholesterol is converted to pregnenolone, which is then converted to progesterone by the enzyme 3-beta-hydroxysteroid dehydrogenase. After ovulation, the collapsed follicle transforms into the corpus luteum, a temporary endocrine gland that secretes progesterone in quantities sufficient to transform the uterine lining from a proliferative state to a secretory state. If pregnancy does not occur, the corpus luteum degenerates after about 12 to 14 days, progesterone drops sharply, and menstruation begins.

At the cellular level, progesterone binds to intracellular progesterone receptors (PR-A and PR-B), which then act as transcription factors, entering the nucleus and altering gene expression. This is how it modifies the endometrium, suppresses uterine contractions, and regulates immune tolerance during pregnancy. Progesterone also has rapid, non-genomic effects. Its metabolite allopregnanolone is a potent positive allosteric modulator of GABA-A receptors, the same class of receptors targeted by benzodiazepines and alcohol. This explains progesterone's sedative, anxiolytic, and anticonvulsant properties.

Progesterone is metabolized primarily in the liver through reduction and conjugation. The route of administration matters: oral micronized progesterone undergoes significant first-pass hepatic metabolism, producing higher levels of allopregnanolone (which enhances the sleep-promoting effect), while transdermal or vaginal routes deliver more progesterone to target tissues with less sedation. Progesterone also serves as a precursor hormone; it can be converted into cortisol, aldosterone, and androgens depending on tissue-specific enzyme expression.

Progesterone does not operate in isolation. It exists in dynamic balance with estrogen, and the ratio between these two hormones often matters more clinically than either level alone. During the follicular phase of the menstrual cycle, estrogen dominates, driving endometrial growth. After ovulation, progesterone rises sharply to mature and stabilize that lining. If this balance tips toward estrogen without adequate progesterone to counterbalance it (a state sometimes called estrogen dominance), the result can be heavy periods, fibroid growth, breast tenderness, and mood instability.

Progesterone also sits upstream in the steroid hormone cascade. As a product of pregnenolone and a precursor to cortisol, aldosterone, and certain androgens, its availability is influenced by adrenal demand. During periods of sustained stress, the body may preferentially convert shared precursors toward cortisol production, reducing the substrate available for progesterone synthesis. This is one reason chronic stress is associated with anovulatory cycles and luteal phase defects. Thyroid hormones further modulate this picture; adequate thyroid function supports ovulation, and therefore progesterone production, while hypothyroidism can impair it.

Low progesterone manifests differently depending on a woman's life stage. In reproductive years, the most recognizable signals are short luteal phases (fewer than 10 days between ovulation and menstruation), premenstrual spotting, heavy or irregular periods, difficulty conceiving, and early pregnancy loss. Sleep disruption that worsens in the second half of the cycle, particularly insomnia or fragmented sleep in the days before menstruation, can also point to insufficient progesterone or an inadequate allopregnanolone response.

During perimenopause, cycles may become anovulatory more frequently, meaning progesterone production drops significantly even while estrogen levels remain normal or fluctuate erratically. This stage often produces symptoms that are mistakenly attributed to estrogen decline: night sweats, anxiety, irritability, and menstrual flooding. Mood changes that appear cyclical or worsen premenstrually deserve evaluation, as they can reflect progesterone insufficiency rather than a psychiatric condition. Basal body temperature charts that no longer show a clear biphasic pattern (a rise after ovulation) suggest anovulation and, by extension, low progesterone.

The most widely prescribed form of bioidentical progesterone is oral micronized progesterone, available as a capsule taken at bedtime. The micronization process increases absorption, and the first-pass liver metabolism generates allopregnanolone, which contributes to the sleep benefit. Doses typically range from 100 mg (for sleep or luteal support in younger women) to 200 mg or more (for endometrial protection in postmenopausal hormone therapy). For women who experience excessive drowsiness or digestive upset with oral forms, vaginal suppositories or capsules deliver progesterone directly to pelvic tissues with less systemic sedation.

Transdermal progesterone creams are available over the counter in some regions, but their absorption is variable and may not achieve serum levels sufficient for endometrial protection. This makes them a less reliable option for women using estrogen replacement who need progesterone to prevent endometrial hyperplasia. Compounded progesterone preparations, available through specialty pharmacies, allow for customized dosing and delivery methods (sublingual troches, topical gels, rectal suppositories) but lack the standardized quality control of FDA-approved products.

Beyond direct supplementation, supporting the body's own progesterone production is worth considering. Adequate vitamin B6 is involved in corpus luteum function. Vitex (chasteberry) has been studied for its ability to modulate pituitary signaling and support luteal phase progesterone, though evidence quality is mixed. Stress reduction, consistent sleep, and addressing thyroid or insulin resistance issues can all support ovulatory cycles and, consequently, endogenous progesterone production.

The largest body of evidence on progesterone supplementation comes from hormone replacement therapy research. Observational data from the French E3N cohort study and other large registries suggest that micronized progesterone, when paired with estrogen, carries a lower breast cancer risk compared to synthetic progestins like medroxyprogesterone acetate. This distinction has shifted clinical practice, though long-term randomized trial data specifically comparing micronized progesterone to placebo remain limited in scope. Multiple small trials support the sleep-promoting effects of oral micronized progesterone, consistent with the known pharmacology of allopregnanolone at GABA-A receptors.

Evidence for progesterone's role in bone health comes largely from mechanistic studies and smaller clinical trials showing additive benefits when progesterone is combined with estrogen for bone density. Its neuroprotective effects, including promotion of myelin repair, have been demonstrated in animal models of traumatic brain injury and demyelinating disease, but human clinical trials in these areas remain early-stage. The overall picture is one of a hormone with well-characterized mechanisms and strong biological plausibility for multiple health benefits, but with clinical trial evidence that is strongest in the reproductive and sleep domains and thinner in areas like cardiovascular protection and neuroregeneration.

Oral micronized progesterone can cause drowsiness, which is why bedtime dosing is standard; this sedation is a feature for some and a side effect for others. Some women experience mood changes, bloating, or headaches. Progesterone is contraindicated in individuals with a known allergy to peanuts (some formulations use peanut oil as a carrier, though alternatives exist). Women with a history of hormone-sensitive cancers should discuss risks with a clinician who understands their full medical history. Synthetic progestins have a different side effect and risk profile from bioidentical progesterone, and the two should not be conflated when evaluating evidence. Self-prescribing over-the-counter progesterone creams without testing can mask underlying conditions or create imbalances.